Barclays lowered the firm’s price target on Revvity to $120 from $130 and keeps an Equal Weight rating on the shares. The analyst previewed the Q3 earnings reports for the life science tools and diagnostics sector and dug into bioprocessing destocking and the risk of National Institutes of Health budget cuts.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on RVTY: